SINGAPORE--The last of 140 patients have been enrolled in a trial of Singapore-based Biosensors International's clinical trial of its drug-coated stent, BioFreedom, according to a news release. The trial is being conducted in Japan by Leaders Free Japan in patients at high risk of bleeding.
The drug-eluting stent is coated with antiplatelet drug Biolimus A9 BA9 intended to last a month on a stent designed to be as safe as bare-metal stents. The drug is an anti-restenotic developed specifically for stents and degrades in 6 to 9 months.
The one-year trial to be conducted at a dozen trial centers across the country is to measure several outcomes such as heart failure myocardial infarction and thrombosis.
- read the statement